PER 0.00% 8.0¢ percheron therapeutics limited

News: ANP Antisense Therapeutics says ATL1102 for MS Phase IIb IND submitted to FDA for review, page-42

  1. 650 Posts.
    lightbulb Created with Sketch. 16
    next voting its gonna hard to vote em down if they control 20% of the conpany... tje amount of votes needed now lol... just lol
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.